top of page

Social Media Toolkit

Ignite Change With Our Social Media Toolkit!

Welcome to Pay Less For RX's Social Media Toolkit – your digital arsenal for advocacy! In the battle against skyrocketing drug prices, your voice matters, and social media is the battleground. This toolkit equips you with compelling content, shareable graphics, and strategic hashtags to amplify our message and spark conversations.
 

Why Social Media?

Social platforms are powerful catalysts for change. With a click, a share, or a hashtag, you can join a movement that demands fair drug pricing, transparency, and accountability from pharmaceutical companies. It's time to leverage the influence of your online community for a cause that impacts us all.

What's Inside?

Explore a curated collection of eye-catching visuals, informative infographics, and engaging content ready for sharing. Whether you're a seasoned advocate or just getting started, our toolkit provides the tools you need to make a meaningful impact. Every post contributes to the collective voice demanding change.

How to Get Started:

  1. Explore Content: Dive into a variety of content covering the intricacies of pharmaceutical pricing, industry practices, and personal stories.

  2. Share Widely: Spread the word by sharing our content on your social platforms. Every share is a step toward raising awareness and driving change.

  3. Use Hashtags: Join the conversation by incorporating campaign hashtags into your posts. This unifies our message and increases visibility.
     

Together, We Can:

It's time to transform social media into a force for change. Join us in the digital realm, be a voice for affordable healthcare, and together, let's make a difference. Explore the Social Media Toolkit now and spark the change we all need!

Social Media

Key Social handles to tag:

• President Biden @POTUS
• Department of Health and Human Services - @HHSGov
• Secretary Xavier Becerra - @SecBecerra
• Centers for Medicare and Medicaid Services - @CMSGov
• Administrator Chiquita Brooks-LaSure - @BrooksLaSureCMS

Key Hashtags:

#PayLessForRX

#NegotiationStartsNow

#MedicareDrugNegotiation

General Messages:

Twitter/X:

  • .@POTUS and @SecBecerra have officially announced the first 10 drugs for which Medicare will have the ability to negotiate the price. This is the first step towards lowering drug prices for millions of patients who rely on Medicare #NegotiationStartsNow #PayLessforRx 
     

  • Every day older adults are skipping doses of their RX drugs. Sadly, they can’t afford them after paying rent, buying groceries and putting gas in their cars. The Medicare drug negotiation program is first step towards
    ending this crisis. #NegotiationStartsNow #PayLessforRx
     

  • The day has finally arrived! @POTUS and @SecBecerra have announced the first 10 drugs up for price negotiations. If you take one of these 10 drugs, your prices are going down in 2026! #NegotiationStartsNow
    #PayLessforRx (Include photo of list of the 10 drugs)
     

  • It’s here! The list is in! These 10 Rx drugs are officially up for price negotiation. We cannot wait to see the impact on patient’s wallets come 2026. #NegotiationStartsNow #PayLessforRx (follow with list of drugs)


Facebook or LinkedIn:

  • In the last year, we’ve seen proof that government action can stop big drug companies from ripping off patients. Congress passed legislation giving Medicare the ability to cap the cost of insulin to $35 per month AND make key vaccines like the shingles shot free for older adults. These policies are providing millions of older adults and people disabilities with more affordable health care. Read more here: https://familiesusa.org/resources/the-difference-a-year-makes-in-the-world-of-medicare-a-look-at-the-impact/
     

  • No more will big drug corporations be allowed to price gouge patients for their own profits #NegotiationStartsNow. Today’s announcement covers 10 Medicare Part D drugs that will now be up for price negotiation, a monumental step forward to lowering drug costs for the millions of older adults and people with disabilities that rely on Medicare. Come 2026, it is time to #PayLessForRX

First 10 Drug Specific Messages

  • Eliquis

    • ​Eliquis was named one of the first 10 Medicare Part D drugs up for price negotiations. This blood thinner, used to treat risk of stroke or blood clots, helps over 3 million people in Medicare #NegotiationStartsNow
       

    • Eliquis cost Medicare Part D $16.4 billion in the last year, meanwhile Bristol Myer Squibb, the company that produces Eliquis, made $36 billion in profit last year. It’s clear it is time to #PayLessForRx
       

  • Xarelto

    • ​Xarelto was named one of the first 10 Medicare Part D drugs up for price negotiations. This blood thinner, used to treat risk of stroke or blood clots, helps over 1 million people in Medicare
      #NegotiationStartsNow

       

    • Xarelto cost Medicare Part D $6.03 billion dollars in the last year, meanwhile Janssen, the company that produces Xarelto, made billions in profit last year. It’s clear it is time to #PayLessForRx
       

  • Januvia

    • ​Januvia was named one of the first 10 Medicare Part D drugs up for price negotiations. This type 2 diabetes treatment helps nearly 1 million people in Medicare #NegotiationStartsNow
       

    • Januvia cost Medicare Part D $4.08 billion dollars in the last year, meanwhile Merck, the company that produces Januvia, made $59 billion last year. It’s clear it is time to  #PayLessForRx
       

  • Jardiance

    • ​Jardiance was named one of the first 10 Medicare Part D drugs up for price negotiations. This type 2 diabetes treatment helps over 1 million people in Medicare #NegotiationStartsNow
       

    • Jardiance cost Medicare Part D $7.05 billion dollars in 2021, meanwhile Boehringer Ingelheim, the company that produces Jardiance, made at least $17 billion last year. It’s clear it is time to
      #PayLessForRx

       

  • Fiasp/NovoLog

    • ​Fiasp was named one of the first 10 Medicare Part D drugs up for price negotiations. This diabetes treatment helps nearly 800,000 people in Medicare #NegotiationStartsNow
       

    • Fiasp cost Medicare Part D $2.5 billion dollars in the last year, meanwhile Novo Nordisk, the company that produces Fiasp, made $25 billion last year. It’s clear it is time to #PayLessForRx
       

  • Enbrel

    • ​Enbrel was named one of the first 10 Medicare Part D drugs up for price negotiations. This autoimmune, including rheumatoid arthritis, treatment helps over 45,000 people in Medicare #NegotiationStartsNow
       

    • Enbrel cost Medicare Part D $2.7 billion dollars in the last year, which is why it will be among the first 10 drugs Medicare will negotiate the price of. Meanwhile Amgen the company that produces Enbrel made $26 billion last year. It’s clear it is time to #PayLessForRx
       

  • Entresto

    • ​Entresto was named one of the first 10 Medicare Part D drugs up for price negotiations. This chronic heart failure treatment helps over 500,000 people in Medicare #NegotiationStartsNow
       

    • Entresto cost Medicare Part D $2.8 billion dollars in the last year, meanwhile Novartis, the company that produces Entresto, made $51 billion last year. It’s clear it is time to #PayLessForRx
       

  • Farxiga

    • ​Farxiga was named one of the first 10 Medicare Part D drugs up for price negotiations. This diabetes, heart failure, or chronic kidney disease treatment helps nearly 800,000 in Medicare
      #NegotiationStartsNow

       

    • Farxiga cost Medicare Part D $3.2 billion dollars in the last year, which is why it will be among the first 10 drugs Medicare will negotiate the price of. Meanwhile Novartis the company that produces Farxiga made $51 billion last year. It’s clear it is time to #PayLessForRx
       

  • Stelara

    • ​Stelara was named one of the first 10 Medicare Part D drugs up for price negotiations. This Psoriasis and Crohn’s disease treatment helps over 20,000 people in Medicare.  #NegotiationStartsNow
       

    • Stelara cost Medicare Part D $2.6 billion dollars. Meanwhile Janssen the company that produces Stelara made billions in profit last year. It’s clear it is time to #PayLessForRx
       

  • Imbruvica

    • ​Imbruvica was named one of the first 10 Medicare Part D drugs up for price negotiations. This treatment for blood cancers helps 20,000 people in Medicare #NegotiationStartsNow
       

    • Imbruvica cost Medicare Part D $2.6 billion dollars, which is why it will be among the first 10 drugs Medicare will negotiate the price of. Meanwhile Abbvie and Janssen, the companies that jointly produce Imbruvica, made at least $58 billion last year. It’s clear it is time to #PayLessForRx

Social Media Graphics

bottom of page